Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member

Search

1732907

	registered interest
	date	09/10/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many patients under the age of 18 are in receipt of an NHS funded cannabis-based (a) prescription and (b) medication.
	tabling member constituency	South Ribble
	tabling member printed	Mr Paul Foster
	uin	8273
	answer	answer is ministerial correction date of answer 14/10/2024 answer text <p>The NHS Business Services Authority does not hold the information in the form requested as it is only a legal requirement for prescriptions to state the age for children under 12 years.</p><p>Between November 2018 and July 2024, 21,299 items of licensed cannabis-based medicines, namely Nabilone, Sativex and Epidyolex, were dispensed in the community in England against a National Health Service prescription.</p><p>Data on unlicensed cannabis-based medicines is withheld in accordance with the General Data Protection Regulation, due to the number of items attributed to fewer than five patients and enhanced risk of release of patient identifiable information.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 14/10/2024 15:33:44 answering member 1506 label Biography information for Andrew Gwynne
	tabling member	5074

1731599

	registered interest
	date	04/10/2024
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what steps she is taking to help ensure police officers are trained to deal appropriately with people who rely on prescribed medical cannabis.
	tabling member constituency	Worthing West
	tabling member printed	Dr Beccy Cooper
	uin	7267
	answer	answer is ministerial correction date of answer 14/10/2024 answer text <p>The Home Office published Circular 018/2018 when Cannabis-Based Products for Medicinal Use (CBPMs) were introduced under Schedule 2 to the Misuse of Drugs Regulations 2001 on 1 November 2018. The circular summarised the effects of the legislation, and is primarily aimed at law enforcement, including the police. It remains available on gov.uk. This guidance applies to all CBPM prescriptions, whether prescribed on the NHS or privately. The Circular is available at the following link: <a href="https://www.gov.uk/government/publications/circular-0182018-rescheduling-of-cannabis-based-products-for-medicinal-use-in-humans" target="_blank">https://www.gov.uk/government/publications/circular-0182018-rescheduling-of-cannabis-based-products-for-medicinal-use-in-humans</a>.</p><p>Additionally, the Home Office and the Department for Health and Social Care contributed to the NHS document <em>‘Medical cannabis (and cannabis oils)’</em>, which includes a summary of how patients may demonstrate that they are in lawful possession. This guidance is available at the following link: <a href="https://www.nhs.uk/conditions/medical-cannabis/" target="_blank">https://www.nhs.uk/conditions/medical-cannabis/</a>.</p> answering member constituency Kingston upon Hull North and Cottingham answering member printed Dame Diana Johnson question first answered 14/10/2024 11:40:44 answering member 1533 label Biography information for Dame Diana Johnson
	tabling member	5307

1689862

	registered interest
	date	19/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people aged under 18 have been prescribed medicinal cannabis as of 19 February 2024.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	14583
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Department does not hold details relating to the age of people prescribed medicinal cannabis.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/02/2024 11:18:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1689392

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans her Department has to make medicinal cannabis more accessible to those who need it.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Paula Barker
	uin	14291
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence (NICE) demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p> </p><p>The Government continues to call on manufacturers to invest in research and clinical trials to prove if their products are safe and effective and offers scientific and research advice from the Medicines and Healthcare products Regulatory Agency and the NICE.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/02/2024 09:43:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4828 label Biography information for Paula Barker

1687065

	registered interest
	date	02/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress she has made with (a) regulatory, (b) research and (c) NHS partners on establishing clinical trials to test the (i) safety and (ii) efficacy of medical cannabis products.
	tabling member constituency	Somerton and Frome
	tabling member printed	Sarah Dyke
	uin	12872
	answer	answer is ministerial correction date of answer 09/02/2024 answer text <p>The Department, via the National Institute for Health and Care Research (NIHR), is developing a programme of two randomised controlled trials to test the safety and efficacy of medicinal cannabis products to treat epilepsy in adults and children. The trials will start as soon as possible, and the results will be published once the trials have completed and the findings peer reviewed.</p><p> </p><p>Furthermore, the Government continues to encourage manufacturers to invest in research and has highlighted that public funding is available for high quality applications. The Medicines and Healthcare products Regulatory Agency and the NIHR can provide applicants with scientific and research advice.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 09/02/2024 10:47:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4995 label Biography information for Sarah Dyke

1682606

	registered interest
	date	16/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the potential merits of allowing children to be issued medical cannabis prescriptions on the NHS.
	tabling member constituency	Somerton and Frome
	tabling member printed	Sarah Dyke
	uin	9974
	answer	answer is ministerial correction date of answer 22/01/2024 answer text <p>Licensed cannabis-based medicines, that have been proved effective in clinical trials and judged cost-effective by the National Institute of Health and Care Excellence (NICE), are routinely available on the National Health Service, including for people aged over two years old with certain types of epilepsy. However, clinical guidelines from NICE demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/01/2024 14:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4995 label Biography information for Sarah Dyke

1681903

	registered interest
	date	15/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of medicinal cannabis treatments provided by the NHS; and whether she has plans to increase the number of treatments available.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	9453
	answer	answer is ministerial correction date of answer 17/01/2024 answer text <p>Licensed cannabis-based medicines are available and funded on the National Health Service, where the safety, quality and clinical and cost effectiveness has been assessed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence.</p><p>The Government continues to encourage manufacturers to develop new treatments and invest in research and clinical trials, and offers scientific and research advice from the MHRA and the National Institute for Health and Care Research.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/01/2024 17:12:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1447 label Biography information for Andrew Rosindell

1681904

	registered interest
	date	15/01/2024
	answering body	Department for Business and Trade
	answering dept id	214
	answering dept short name	Business and Trade
	answering dept sort name	Business and Trade
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State of Business and Trade, what estimate she has made of the contribution of domestic medicinal cannabis production to the economy.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	9454
	answer	answer is ministerial correction date of answer 23/01/2024 answer text <p>The Department for Business and Trade (DBT) actively assists life sciences companies in their endeavours to invest, expand, and export, thereby generating employment and economic growth.</p><p>UK-based life sciences businesses receive support from DBT through trade missions to key markets, participation in major trade events, tackling market access barriers, upskilling exporters, and guidance on entering new markets. Although routine assessments of the economic impact of specific life sciences’ subsectors like medicinal cannabis are not conducted, DBT is committed to supporting companies of various sizes throughout their export and inward investment endeavours while adhering to national regulatory guidelines.</p> answering member constituency Thirsk and Malton answering member printed Kevin Hollinrake question first answered 23/01/2024 17:59:05 answering member 4474 label Biography information for Kevin Hollinrake
	tabling member	1447 label Biography information for Andrew Rosindell

1663633

	registered interest
	date	13/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Government is taking steps to reduce inequalities in access to medicinal cannabis prescribed under the NHS.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	201487
	answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed products is subject to local National Health Service decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 14:43:27 answering member 4423 label Biography information for Will Quince
	tabling member	4079 label Biography information for Julian Sturdy

1663778

	registered interest
	date	13/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will take steps to increase access to cannabis-based medicinal products on the NHS.
	tabling member constituency	Ealing Central and Acton
	tabling member printed	Dr Rupa Huq
	uin	201631
	answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed products is subject to local NHS decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality and clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 11:14:45 answering member 4423 label Biography information for Will Quince
	tabling member	4511 label Biography information for Dr Rupa Huq